Results Presentation
1Q of FY Ending March 2025
WIN-Partners Co., Ltd. (3183)

1Q results to June 2024

Highlights⚫ The number of cases in major segments increased YoY⚫ Gross profit margin temporally fell YoY due to sales
mix change and the impact of the reimbursement
price revision⚫ Operating profit substantially increased YoY as anincrease in SGA was modest due partly to an absenceof one-off expenses3Consolidated results summary（¥ mil.）1Q toJun. 2023

Jun. 2024

YoY (%)

Sales17,383+12.8－Operating profit

432

Recurring profit435Net profit

290

EPS (yen)

10.23

19,603
586
587
396
13.89

BPS (yen)761.81782.80+35.6+35.0+36.5－4

SalesYoY+12.8%(¥ mil.)19,603
17,383

1Q to Jun. 2023

1Q to Jun. 2024⚫

Sales of all segments increased YoY⚫

Sales of CRS and CVS, on which WIN has been focusing,were strong⚫

Sales of large-scale medical equipment increased
5

Sales breakdown by segment (YoY)
Segment

Sales（¥ mil.）YoY growth (%)
VolumeValue% of sales(%)

Percutaneous coronary intervention (PCI)

4,603+0.5+6.8

23.5

Cardiac rhythm segment (CRS)

5,233+11.4+9.6

26.7

Cardiac vascular segment (CVS)

3,684+3.2+21.1

18.8

Percutaneous peripheral intervention (PPI)

1,159+8.0

+6.0

5.9

956+3.5+5.1

4.9

NeurovascularDiabetes mellitus segment (DMS)

1,041-+22.3

5.3

Medical equipment

1,343-+47.0

6.8

Others

1,581-+6.4

8.1

19,603-+12.8

100.0

Total

6Operating profit
YoY+35.6%(¥ mil.)586

432

1Q to Jun. 2023

1Q to Jun. 2024

⚫ Gross profit margin 12.1% (-0.3 pp YoY)
- Sales mix changed- Reimbursement price revision staggered price negotiations and rebate programs⚫ SGA +4.0% YoY- Labor costs increased YoY- Other expenses decreased YoY partly because one-off expenses (including
10th anniversary-related cost) striped off- Number of employees: 634 (Jun. 2023) → 638 (Jun. 2024)

7

Initiatives for human capital
We set the following KPIs to promote the development of human resources that
support sustainable corporate activities and diversity to enable employees todemonstrate their skills and talents
KPI

FY2023
Targets/Results

FY2024
Targets

Utilization rate of staggered working hours and flextime

Target: 65.0%
Results: 68.1%

Target: 70.0%

Utilization rate of level-based education lessons and education
tools for self-enlightenment

Target: 60.0%
Results: 67.4%

Target: 70.0%

Maintain 25% female employment ratio

Target: 25.0%
Results: 38.3%

Target: 25.0%

Percentage of promotion-to-manager recommendations forfemale employees

Target: 20.0％(3-year average)
Result: 21.0%(2-years average)

Target: 20.0％(3-year average)

Participation of female employees in KIRARIS meetings (a support
team for female employees)

Target: 80.0%
Results: 89.5%

Target: 80.0%

Percentage of male employees taking childcare leave

Target: 45.0%
Results: 44.4%

Target: 50.0%

Thorough education on compliance and human rights(Percentage of employees attending lectures)

Target: 100.0%
Results: 100.0%

Target: 100.0%
8

References

Sales impact by the reimbursement
price revision in April
Segment

Assumedimpact (%)

Percutaneous Coronary Intervention (PCI)-4.0Cardiac Rhythm Segment (CRS)-2.3

Cardiac Vascular Segment (CVS)-0.4

Percutaneous Peripheral Intervension (PPI)-2.3

Brain Surgery-0.3

Others

-0.4

Total

-1.7

Calculated based on the actual sales volume and product mix for FY ended March 2024(June～March)

10

Reimbursement prices ofmajor products
Segment

PCIItems
PTCA balloon catheter
Drug eluting stent (DES)PPI
Neurovascular2024(Jun.)

Change (%)

29
120
66

593
2,820
3,260
3,120
117
649
1,320
1,110

516
2,660
3,260
3,120
112
649
1,320
1,110

- 9.4
- 11.8- 8.3- 13.0- 5.7
0.00.0- 4.3
0.0
0.00.0

Hea rt va l ve for tra ns ca theter a orti c va l ve i mpl a nta ti on(TAVI) (ba l l oon-expa nda bl e)

4,510

4,5100.0

Heart valve for TAVI (self-expandable)
PTA balloon catheter
Peripheral vascular stent
Peripheral drug eluting stent (DES)
Embolic coil (electric type)
Thrombectomy catheter (self-expandable)

3,740
50160
233
117
386

3,740
47159
233
116
386

0.0
- 6.3
- 0.60.0- 0.90.0

PacemakerImplantable cardioveter defibrillator (ICD)

CVS

2022(Apr.)
32
136
72

Intravascular ultrasound (IVUS) catheter

CRS

Reimbursement prices (¥000)

Cardiac resychronization therapy defibrillator (CRTD)

Subcutaneous implantable defibrillator (S-ICD）
Ablation catheter
Cardiac cryoablation catheter
Stent graft (abdomen）
Open stent graft

11

Disclaimer
This material was prepared based on the information available and the views held at the time it was made. Statements in thismaterial that are not historical facts, including but not limited to plans, forecasts and strategies are “forward-looking statements.”
Forward-looking statements are by their nature subject to various risks and uncertainties, including but not limited to a decline ingeneral economic conditions, general market conditions, technological developments, changes in customer demand for products
and services, increased competition, and other important factors, each of which may cause actual results and future developments
to differ materially from those expressed or implied in any forward-looking statement.
With the passage of time, the information in this material (including but not limited to forward-looking statements) could besuperseded or cease to be accurate. WIN-Partners Co., Ltd. disclaims any obligation or responsibility to update, revise, orsupplement any forward-looking statement or other information in any material or generally to any extent. The utilization of orreliance on the information in this material is at your own risk.

Contact
WIN-Partners Co., Ltd.
Investor Relations
Phone: +81-3-3548-0790
https://www.win-partners.co.jp/en/

Click here for thehomepage →